SEARCH

SEARCH BY CITATION

References

  • Aid S. and Bosetti F. (2007) Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res. Bull. 73, 108113.
  • Aid S., Langenbach R. and Bosetti F. (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J. Neuroinflammation 5, 17.
  • Aid S., Silva A. C., Candelario-Jalil E., Choi S. H., Rosenberg G. A. and Bosetti F. (2010) Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J. Cereb. Blood Flow Metab. 30, 370380.
  • Albensi B. C. and Mattson M. P. (2000) Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 35, 151159.
  • Aronoff D. M., Canetti C. and Peters-Golden M. (2004) Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173, 559565.
  • Atzori C., Ghetti B., Piva R., Srinivasan A. N., Zolo P., Delisle M. B., Mirra S. S. and Migheli A. (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J. Neuropathol. Exp. Neurol. 60, 11901197.
  • Bate C., Veerhuis R., Eikelenboom P. and Williams A. (2003) Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. NeuroReport 14, 20992103.
  • Block M. L., Zecca L. and Hong J. S. (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 5769.
  • Breitner J. C., Baker L. D., Montine T. J. et al. ADAPT Research Group (2011) Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 7, 402411.
  • Bruce A. J., Boling W., Kindy M. S., Peschon J., Kraemer P. J., Carpenter M. K., Holtsberg F. W. and Mattson M. P. (1996) Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med. 2, 788794.
  • Choi S. H. and Bosetti F. (2009) Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) 1, 234244.
  • Choi S. H., Langenbach R. and Bosetti F. (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 22, 14911501.
  • Choi S. H., Aid S. and Bosetti F. (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci. 30, 174181.
  • Choi S. H., Aid S., Choi U. and Bosetti F. (2010) Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J. 10, 448457.
  • Coma M., Sereno L., Da Rocha-Souto B. et al. (2010) Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 38, 482491.
  • Cramer P. E., Cirrito J. R., Wesson D. W. et al. (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 15031506.
  • Dargahi L., Nasiraei-Moghadam S., Abdi A., Khalaj L., Moradi F. and Ahmadiani A. (2011) Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Abeta-induced neuroinflammation. J. Mol. Neurosci. 45, 1021.
  • Escribano L., Simon A. M., Gimeno E. et al. (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 15931604.
  • Garcia-Bueno B., Serrats J. and Sawchenko P. E. (2009) Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli. J. Neurosci. 29, 1297012981.
  • Goedert M., Jakes R. and Vanmechelen E. (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci. Lett. 189, 167169.
  • Haga S., Akai K. and Ishii T. (1989) Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol. 77, 569575.
  • Heneka M. T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 14421453.
  • Hickman S. E., Allison E. K. and El Khoury J. (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 83548360.
  • Hoozemans J. J., Rozemuller A. J., Janssen I., De Groot C. J., Veerhuis R. and Eikelenboom P. (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101, 28.
  • Hoozemans J. J., Veerhuis R., Janssen I., van Elk E. J., Rozemuller A. J. and Eikelenboom P. (2002) The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res. 951, 218226.
  • Hoozemans J. J., Rozemuller J. M., van Haastert E. S., Veerhuis R. and Eikelenboom P. (2008) Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des. 14, 14191427.
  • Iqbal K., Alonso Adel C., Chen S. et al. (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198210.
  • Jantzen P. T., Connor K. E., DiCarlo G., Wenk G. L., Wallace J. L., Rojiani A. M., Coppola D., Morgan D. and Gordon M. N. (2002) Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 22462254.
  • Jimenez S., Baglietto-Vargas D., Caballero C. et al. (2008) Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 28, 1165011661.
  • Keene C. D., Chang R. C., Lopez-Yglesias A. H. et al. (2010) Suppressed accumulation of cerebral amyloid beta peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am. J. Pathol. 177, 346354.
  • Koenigsknecht-Talboo J. and Landreth G. E. (2005) Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25, 82408249.
  • Kotilinek L. A., Westerman M. A., Wang Q. et al. (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651664.
  • Liang X., Wang Q., Hand T., Wu L., Breyer R. M., Montine T. J. and Andreasson K. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25, 1018010187.
  • Lim G. P., Yang F., Chu T. et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 57095714.
  • Lim G. P., Yang F., Chu T. et al. (2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22, 983991.
  • Matousek S. B., Hein A. M., Shaftel S. S., Olschowka J. A., Kyrkanides S. and O'Banion M. K. (2010) Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J. Neurochem. 114, 247258.
  • Mattson M. P. (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631639.
  • McGeer P. L. and McGeer E. G. (2007) NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28, 639647.
  • McGeer P. L., Itagaki S., Tago H. and McGeer E. G. (1987) Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79, 195200.
  • McKee A. C., Carreras I., Hossain L. et al. (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 1207, 225236.
  • Oddo S., Caccamo A., Shepherd J. D. et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409421.
  • Oddo S., Caccamo A., Smith I. F., Green K. N. and LaFerla F. M. (2006a) A dynamic relationship between intracellular and extracellular pools of Abeta. Am. J. Pathol. 168, 184194.
  • Oddo S., Caccamo A., Tran L., Lambert M. P., Glabe C. G., Klein W. L. and LaFerla F. M. (2006b) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281, 15991604.
  • Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D. H. and LaFerla F. M. (2006c) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281, 3941339423.
  • Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D. H. and LaFerla F. M. (2008) Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J. Neurosci. 28, 1216312175.
  • Peress N. S., Fleit H. B., Perillo E., Kuljis R. and Pezzullo C. (1993) Identification of Fc gamma RI, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer's disease. J. Neuroimmunol. 48, 7179.
  • Sherman M. Y. and Goldberg A. L. (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29, 1532.
  • Smith C. J., Zhang Y., Koboldt C. M. et al. (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl Acad. Sci. USA 95, 1331313318.
  • Sung S., Yang H., Uryu K., Lee E. B., Zhao L., Shineman D., Trojanowski J. Q., Lee V. M. and Pratico D. (2004) Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 165, 21972206.
  • Sutherland C., Leighton I. A. and Cohen P. (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296(Pt 1), 1519.
  • Vinals M., Bermudez I., Llaverias G., Alegret M., Sanchez R. M., Vazquez-Carrera M. and Laguna J. C. (2005) Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc. Res. 66, 141149.
  • Walker M. C., Kurumbail R. G., Kiefer J. R., Moreland K. T., Koboldt C. M., Isakson P. C., Seibert K. and Gierse J. K. (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem. J. 357, 709718.
  • Wilcock D. M., Gordon M. N. and Morgan D. (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat. Protoc. 1, 15911595.
  • Wisniewski H. M., Wegiel J., Wang K. C. and Lach B. (1992) Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol. 84, 117127.
  • Wyss-Coray T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 10051015.
  • Yermakova A. V., Rollins J., Callahan L. M., Rogers J. and O'Banion M. K. (1999) Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J. Neuropathol. Exp. Neurol. 58, 11351146.